Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL |
| |
Authors: | Hess G Flohr T Derigs H G |
| |
Affiliation: | III. Department of Medicine, Johannes Gutenberg-University, Mainz, Germany. |
| |
Abstract: | In vivo purging may avoid relapse after high dose therapy (HDT) for relapsed lymphoma. Therefore, we have evaluated feasibility and efficacy of Rituximab as in vivo purging agent included into a sequential salvage protocol for CD20+ B-NHL in chemosensitive relapse or induction failure. Thirty seven patients were treated within this protocol and in 36/37 a stem cell product could be acquired with rare NHL contamination. Overall, due to the intensity of treatment there has been a substantial morbidity, including high rates of viral reactivation. However, only one patient died during treatment due to sepsis. Response rates were favourable with an overall response rate of 97% (with 30/35CR). With a maximum follow up of 3.5 years, 15 patients relapsed. Overall, the treatment protocol has proven feasible with high purging efficiency and encouraging remission rates in this unfavourable patient group. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|